Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981–2014: a retrospective observational study

Published on Nov 16, 2015in BMJ Open2.376
· DOI :10.1136/bmjopen-2015-009333
Derek J. Ward8
Estimated H-index: 8
(University of Birmingham),
Edward Hammond1
Estimated H-index: 1
(University of Birmingham)
+ 1 AuthorsAndrew Stevens30
Estimated H-index: 30
(University of Birmingham)
Objectives Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s. Design and setting Retrospective observational study of all new antiviral drugs licensed for use in the UK. Primary and secondary outcome measures Duration of clinical development (from initiation of studies in humans to receipt of Marketing Authorisation), subdivided into clinical trial and regulatory approval periods by the date of Marketing Authorisation Application. Results 48 new antiviral drugs were licensed for use in the UK between 1981 and 2014 (inclusive), over half (54%) initially for HIV infection. The overall mean duration of clinical development was 77.2 months, of which 64.6 months was spent in clinical trials before regulatory submission. The total time in clinical development increased from 41.7 months for drugs licensed 1981–1992 to 91.7 months for drugs licensed 2004–2014. This increase was accounted for by an increase in the clinical trials period and not the regulatory approval period, for which there was no observable trend. Drugs initially licensed to treat hepatitis C had a longer duration of clinical development than those indicated for other viral infections. However, the, initially shorter clinical development durations of drugs indicated for HIV infection increased more rapidly across the study period than those indicated for other viral infections. Conclusions The time spent by antiviral drugs in clinical development has increased markedly in recent decades despite many initiatives to speed access to innovative new drugs. However, this represents only one part of the translational research pathway, and a complete picture of development timeframes is lacking.
  • References (28)
  • Citations (2)
📖 Papers frequently viewed together
1 Citations
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Bengt Jönsson (HHS: Stockholm School of Economics)H-Index: 74
Abstract This paper reviews the issues involved in undertaking HTA studies early in the development of new cancer therapies, and discusses the data and methods for estimating the cost-effectiveness of new diagnostics and treatments. The value for patients of new cancer therapies is based on access to the treatment and optimal use. Realising potential value depends on successful completion of a series of steps, from the initial economic evaluations based on clinical trial data, to the reimburseme...
10 CitationsSource
This analysis of changes in the length of clinical trials over time provides evidence of increased efficiency in drug development and investigates the possible contributing factors.
5 CitationsSource
#1H‐G Eichler (European Medicines Agency)H-Index: 1
#2Lynn G. Baird (MIT: Massachusetts Institute of Technology)H-Index: 5
Last. Gigi Hirsch (MIT: Massachusetts Institute of Technology)H-Index: 7
view all 41 authors...
The concept ofadaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name ofAL should be broadened.Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future.The key drivers include: growing patient demand for timely access to promising therapies, emerging scienceleading to fragmentation of treatmentpopulations, ri...
115 CitationsSource
#1Stephen Hanney (Brunel University London)H-Index: 21
#2Sophie Castle-Clarke (AN: RAND Corporation)H-Index: 5
Last. Steven Wooding (AN: RAND Corporation)H-Index: 14
view all 10 authors...
Background: The time taken, or ‘time lags’, between biomedical/health research and its translation into health improvements is receiving growing attention. Reducing time lags should increase rates of return to such research. However, ways to measure time lags are under-developed, with little attention on where time lags arise within overall timelines. The process marker model has been proposed as a better way forward than the current focus on an increasingly complex series of translation ‘gaps’....
100 CitationsSource
#1Lynn G. Baird (MIT: Massachusetts Institute of Technology)H-Index: 5
#2R. BankenH-Index: 1
Last. Gigi Hirsch (MIT: Massachusetts Institute of Technology)H-Index: 7
view all 14 authors...
There is consensus among stakeholders—patients, providers, academic researchers, regulators, health technology assess-ment (HTA) bodies/payers (who may or may not be in the same organizations depending on the region/country), and the pharmaceutical industry—agreement that an important goal of today’s health-care system is to provide patients timely access to new and meaningfully better medicines at reasonable costs. However, the current “siloed” system of biomedical innova-tion increases develop...
54 CitationsSource
#1Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
#2Gregory K. Folkers (NIH: National Institutes of Health)H-Index: 15
Last. Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 4 authors...
Emerging viral diseases pose ongoing health threats, particularly in an era of globalization; however, new biomedical research technologies such as genome sequencing and structure-based vaccine and drug design have improved our ability to respond to viral threats.
47 CitationsSource
When the late Freddie Mercury penned these words (1), perhaps he had in mind bringing innovative medicines and devices to patients more quickly.
1 CitationsSource
#2Patricia DeverkaH-Index: 1
Last. Emily RosenbergH-Index: 1
view all 4 authors...
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies - Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. A literature review helped elucidate concepts and define focus. The authors then conducted semi-structured interviews with an international sample of 19 senior pharmaceutical executives in various positions in the five companies - R&D, outcomes research, medical affair...
4 CitationsSource
#1Michael HayH-Index: 1
#2David W. ThomasH-Index: 2
Last. Jesse RosenthalH-Index: 1
view all 5 authors...
The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.
867 CitationsSource
19 CitationsSource
Cited By2
#1Kyle Roy Myers (Harvard University)
#2Mark V. Pauly (UPenn: University of Pennsylvania)H-Index: 64
#1Derek J. Ward (University of Birmingham)H-Index: 8
#2Lucy Doos (University of Birmingham)H-Index: 7
Last. Andrew Stevens (University of Birmingham)H-Index: 30
view all 3 authors...
Objectives To investigate the trend in the launch price of new drugs for five common health conditions. Design Cross-sectional study using data on new drugs launched in the UK between 1981 and 2015 for hypertension, asthma, rheumatoid arthritis, schizophrenia and colorectal cancer. Data and sources All drugs marketed in the UK between 1981 and 2015 (inclusive), and licensed specifically for the treatment of one of the five chosen conditions were included in the study. Newly launched medicines an...